<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631843</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.725</article-id><article-id pub-id-type="publisher-id">ofx163.725</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wire</surname><given-names>Mary Beth</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>Marion</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Maggie</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Arumugham</surname><given-names>Thangam</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Dunn</surname><given-names>John</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Naderer</surname><given-names>Odin</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Chimerix</institution>, <addr-line>Durham, North Carolina</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 139. Adult Viral Infection</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S311</fpage><lpage>S311</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.725.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>BCV is a lipid conjugate nucleotide that has shown rapid viral clearance in patients with adenovirus infection and improved survival in animal models of smallpox. In preclinical studies in rats, IV BCV dosed twice weekly for up to 29&#x000a0;days was not associated with gastrointestinal (GI), hematopoietic, hepatic, or renal toxicity. This study evaluated the safety and PK of IV BCV in healthy subjects.</p></sec><sec id="s2"><title>Methods</title><p>In this double-blind study, subjects were randomized 3:1 to receive IV BCV or placebo in sequential single ascending dose cohorts (Table&#x000a0;1). Plasma PK samples were collected over 7&#x000a0;days and assayed by HPLC-MS. Plasma BCV PK parameters were determined by non-compartmental analysis and dose proportionality was assessed. Safety assessments were collected over 14&#x000a0;days.</p></sec><sec id="s3"><title>Results</title><p>Forty healthy male subjects (18&#x02013;46&#x000a0;years, 83% White) were enrolled and completed the study. Plasma BCV Cmax and AUC&#x0221e; increased in proportion to dose (Table&#x000a0;1). AEs and alanine aminotransferase (ALT) elevations were dose- and infusion duration-related (Table&#x000a0;1). GI AEs were mild. All AEs and ALT elevations were transient and no serious AEs occurred.</p><table-wrap id="T1" orientation="portrait" position="float"><caption><p>Table&#x000a0;1. IV BCV PK and Safety</p></caption><table frame="box" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">BCV 10&#x000a0;mg
2&#x000a0;h Infusion
(<italic>n =</italic> 6)</th><th align="center" valign="bottom" rowspan="1" colspan="1">BCV 25&#x000a0;mg
2&#x000a0;h Infusion
(<italic>n =</italic> 6)</th><th align="center" valign="bottom" rowspan="1" colspan="1">BCV 50&#x000a0;mg
2&#x000a0;h Infusion
(<italic>n =</italic> 9)</th><th align="center" valign="bottom" rowspan="1" colspan="1">BCV 50&#x000a0;mg
4&#x000a0;h Infusion
(<italic>n =</italic> 9)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pooled Placebo
(<italic>n =</italic> 10)</th></tr></thead><tbody><tr><td align="left" colspan="6" valign="bottom" rowspan="1">Plasma BCV PK</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Cmax (ng/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">613
(25%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1412
(27%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2952
(19%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1586
(14%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">AUC&#x0221e; (ng h/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1312
(26%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2889
(37%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5948
(19%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">6570
(15%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" colspan="6" valign="bottom" rowspan="1">Drug-related AEs</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (11%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3 (33%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Nausea</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (22%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Decreased appetite</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (11%)</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Headache</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (22%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (22%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Pain, phlebitis at infusion site</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (11%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Elevated liver transaminases<sup>a</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (11%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="fn-2001"><p>Cmax and AUC&#x0221e; presented as geometric mean (%CVb).</p></fn><fn id="fn-2002"><p>
<sup>a</sup>ALT &#x0003e;2x ULN in 2 BCV 50&#x000a0;mg 4h infusion and 1 placebo subjects; 1 ALT elevation considered an AE.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s44"><title>Conclusion</title><p> Single doses of BCV 10&#x02013;50&#x000a0;mg administered as a 2h IV infusion were well tolerated and not associated with significant clinical or laboratory abnormalities. BCV IV 10&#x000a0;mg and BCV IV 50&#x000a0;mg achieved geometric mean plasma BCV AUC&#x0221e; similar to and 4.5-fold, respectively, values achieved with BCV oral 100&#x000a0;mg tablets (Cmax&#x000a0;=&#x000a0;251&#x000a0;ng/mL and AUC&#x0221e;&#x000a0;=&#x000a0;1394&#x000a0;ng hours/mL). These data support evaluation of repeat dose administration in healthy subjects and virally-infected patients.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>M. B.&#x000a0;Wire</bold>, Chimerix: Employee and Shareholder, Salary. <bold>M. Morrison</bold>, Chimerix: Employee and Shareholder, Salary.<bold>M. Anderson</bold>, Chimerix: Employee and Shareholder, Salary. <bold>T. Arumugham</bold>, Chimerix: Employee and Shareholder, Salary. <bold>J. Dunn</bold>, Chimerix: Employee and Shareholder, Salary. <bold>O. Naderer</bold>, Chimerix: Employee and Shareholder, Salary.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>